Bora Wins Prestigious CDMO Leadership Awards TAIPEI, TAIWAN, March 20, 2025 – Bora Pharmaceuticals Co., Ltd. (“Bora” or “the
SAN DIEGO, CA – January 20, 2025 – Tanvex BioPharma, Inc. (“Tanvex”), a contract development and manufacturing organization (CDMO) for
Bora Biologics Announces Strategic Collaboration to Accelerate Key CMC Development of DotBio’s Tri-Specific Antibody to Treat Cancer TAIPEI, TAIWAN –
Bora Pharmaceuticals Announces Unveiling of New Multi-Purpose Small Molecule Site in Zhongli, Taiwan Taipei, Taiwan (January 6, 2025) – Bora
Bora Pharmaceuticals Wins Dual Honors at the Taiwan MAPECT M&A Ceremony: “Deal of the Year” Award and “Best Cross-Border M&A”
Taipei, Taiwan, October 25, 2024 – Bora Pharmaceuticals Co., Ltd. (“Bora” or “the Company”, TWSE: 6472), today announced that its
Taipei, Taiwan, August 27, 2024 – Bora Pharmaceuticals Co., Ltd. (“Bora” or “the Company”, TWSE: 6472), today announced that
TAIPEI, TAIWAN, August 20th 2024 – Bora Pharmaceuticals Co., Ltd. (“Bora” or “the Company”, TWSE: 6472), a a global leader
Taiwan, 8th December 2023: As being the largest pharmaceutical company in Taiwan, we are proud to announce that Bora Pharmaceuticals was honored
